BACKGROUND: Nonresponsiveness to clopidogrel and acetylsalicylic acid (ASA), a frequent result of platelet aggregometry studies, has unclear clinical and prognostic significance.
Inhibition of platelet aggregation is a major therapeutic goal for patients with coronary artery disease (CAD) 5 after percutaneous coronary intervention (PCI) to prevent adverse cardiovascular events, such as acute myocardial infarction, stent thrombosis, or cardiovascular death (1) (2) (3) . Up to one-third of these patients exhibit normal platelet aggregation in spite of dual antiplatelet therapy with acetylsalicylic acid (ASA) and clopidogrel. This phenomenon is often referred to as nonresponsiveness or, more commonly, antiplatelet drug resistance (4, 5 ) . Despite the relatively high frequency of the laboratory diagnosis "resistance," a much lower frequency of cardiovascular events, e.g., 1%-2% for stent thrombosis, is observed after PCI. This disparity has raised doubts about the clinical importance of platelet aggregometry.
The reasons for nonresponsiveness to antiplatelet treatment may vary and are not fully understood. Compliance to treatment, bioavailability, enzyme activities, and genetic polymorphisms may play a role (4 ) . Previous reports have focused on studying the response to either clopidogrel or ASA, but only a few studies have examined the responses to both ASA and clopidogrel. Such studies are difficult to perform because standardized assays for aggregometry are lacking (6 ) . Recently, we validated assays using impedance aggregometry to study the aggregation responses to ASA and clopidogrel (7, 8 ) . We enhanced the specificity of these assays by in vitro incubation of blood samples with ASA or methyl-S-adenosine monophos-phate (Me-S-AMP), a selective ADP-(P2Y 12 )-receptor blocker. This additional incubation step facilitated the distinction between pharmacodynamic and pharmacokinetic types of resistance. This information is helpful for patient management because platelet inhibition can be improved by increased doses of clopidogrel and/or ASA in patients with a pharmacokinetic resistance. In comparison, pharmacodynamic resistance is less frequent (with a prevalence of approximately 2%) but requires switching to an alternative antiplatelet drug (7, 8 ) .
Our study focused on patients with dual resistance (nonresponders to both ASA and clopidogrel). Compared to responders-patients with adequately inhibited aggregation by either ASA or clopidogrel or boththese dual nonresponders suffered more adverse cardiovascular events during follow-up after PCI.
Materials and Methods

PATIENTS
We carried out this prospective, open-label, noncontrolled, nonrandomized observational cohort study to determine the usefulness of impedance aggregometry for cardiovascular risk stratification in CAD patients who underwent PCI and received standard therapy including ASA and clopidogrel. The specific aim was to examine the aggregation responses to ASA and clopidogrel and correlate them with clinical outcomes, which were assessed by phone interviews or information retrieved from patient charts and documents. The combined primary study endpoint was the first occurrence of any of the following cardiovascular events: cardiovascular death, myocardial infarction, target vessel revascularization, or stent thrombosis occurring 30 days or later after PCI.
We identified a cohort of 182 CAD patients (130 men and 52 women) in an open registry that was approved by the local ethics review board. These patients consecutively underwent PCI for various indications at the University Hospital Heidelberg and included patients with acute coronary syndromes (ACS), suspected CAD, or suspected progression of known CAD. Their medical therapy varied and was not controlled (e.g., use of statins or calcium channel blockers).
Emergency patients with ACS received 0.5 g ASA intravenously and an oral loading dose of 600 mg clopidogrel before PCI. Electively hospitalized patients with suspected CAD or suspected progression of CAD received 0.5 g ASA intravenously before and a loading dose of 600 mg clopidogrel immediately after PCI and stenting. A single bolus of unfractionated heparin (10 000 U) was given immediately be-fore PCI. The type of stent used for PCI was left at the discretion of the operator. After PCI, all patients received maintenance doses of 100 mg ASA and 75 mg clopidogrel once daily.
Patients without CAD and therefore no need for PCI or dual antiplatelet therapy, as well as patients treated with glycoprotein IIb/IIIa receptor inhibitors or thrombolytic agents, were excluded.
AGGREGOMETRY
We performed whole-blood impedance aggregometry the day after clopidogrel loading using described protocols for the CA560 lumi-aggregometer (ChronoLog) (7, 8 ) . In brief, aggregation was determined by measuring the increase in impedance (⍀) between a pair of metal electrodes immersed in whole blood diluted 1:1 with NaCl (9 g/L). Aggregation was started by the addition of ADP at a final concentration of 5 mol/L for the determination of the response to clopidogrel. A clopidogrel nonresponder was identified if the impedance exceeded 5 ⍀ after 6 min of aggregation. In this case, the sample was incubated in vitro with 0.1 mmol/L Me-S-AMP for 20 min to maximize ADP-receptor inhibition. We repeated aggregometry, and if the incubation step improved platelet inhibition (i.e., the 6-min impedance was reduced to values Յ5 ⍀), we assumed a pharmacokinetic rather than a pharmacodynamic type of resistance. Collagen (1 mg/L) was used as platelet agonist in a similar fashion. We assumed nonresponsiveness to ASA if the 6-min impedance exceeded 8 ⍀.
In this case, we analyzed the sample again after in vitro incubation with 0.1 mmol/L ASA for 20 min. If 6-min impedance was then reduced to Յ8 ⍀, we diagnosed a pharmacokinetic rather than a pharmacodynamic type of resistance.
STATISTICAL ANALYSIS
We compared categorical variables and relative proportions using Fisher exact tests and odds ratio and 95% CI, respectively. Continuous variables were summarized using median and 95% CI and were compared using Mann-Whitney U tests. A P value Ͻ0.05 was considered significant. We graphed cumulative cardiovascular event rates using Kaplan-Meier plots, which were compared using log rank tests. We used Cox regression to identify independent determinants of the primary endpoint. Hazard ratios (HRs) and 95% CIs were calculated.
Results
From June 2006 to August 2006, 182 patients underwent PCI and were followed. Median follow-up was 419 days (95% CI 414 -420 days) with a minimum of 4 and a maximum of 511 days. A major finding was that primary endpoint frequencies were not found to differ significantly between fully responsive patients and single nonresponders to clopidogrel. Notably, no adverse event occurred in the group of single nonresponders to ASA. Therefore, we combined single nonresponders and fully responsive subjects into 1 group, hereafter referred to as responders, as opposed to the group of dual nonresponders.
BASELINE CHARACTERISTICS
There were no statistically significant differences in baseline characteristics between dual nonresponders and responders (Table 1) . Stable angina was more frequent in responders (P ϭ 0.051) and severely impaired left ventricular function was noted more often in nonresponders (P ϭ 0.069); procedural parameters, such as the use of a drug-eluting stent (DES) or bare-metal stent (BMS), were comparable (Table 1 ). In total, 141 BMSs and 122 DESs were used. Vision™ (Abbott Vascular Inc.) stents (n ϭ 88) and Endeavour™ (Medtronic Inc.) stents (n ϭ 71) were the most frequently used. The median number of stents used per patient was 1.4, and the median total stent length was 18 mm (95% CI 16.0 -23.0).
Nonresponsiveness to ASA and clopidogrel was found in 33 (18.1%) and 34 (18.7%) of 182 patients, respectively. Nineteen patients (10.4%) were dual nonresponders to both ASA and clopidogrel, whereas 134 (73.6%) patients were fully responsive to both drugs. a Data are n (%) unless noted otherwise. There were no significant (P Ͻ0.05) differences between these groups.
Single nonresponsiveness to either ASA or clopidogrel was found in 14 and 15 patients, respectively. A pharmacokinetic type of resistance was diagnosed in all 15 clopidogrel nonresponders and in 10 of 14 ASA nonresponders.
PRIMARY OUTCOME
A combined primary endpoint occurred in 26 of all 182 (14.3%) patients. In detail, there were 6 (18.1%) and 8 (23.5%) events in 33 and 34 nonresponders to ASA and clopidogrel, respectively, but the majority of these endpoints occurred in patients with dual resistance. There were only 2 (13.3%) events in 15 single nonresponders to clopidogrel. Single nonresponsiveness to ASA was not associated with any event. In comparison, 18 (13.4%) of 134 full responders suffered a primary endpoint. Because endpoint frequencies were comparable between single nonresponders to either ASA or clopidogrel and fully responsive subjects, we combined these 3 groups into 1 group designated responders, with 20 (12.3%) events in 163 subjects ( Table 2 ). In contrast, events were noted in 6 of 19 (31.6%) dual nonresponders ( Table 2 ). In comparison to responders, dual nonresponders had a significantly higher cardiovascular risk (relative risk 2.57, 95% CI 1.18 -5.61). Primary endpoints occurred early during follow-up in dual nonresponders (Fig. 1 ). Multivariate analysis confirmed dual nonresponsiveness (HR 2.9, 95% CI 1.17-7.2, P ϭ 0.02) and age (HR 1.04, 95% CI 1.00 -1.09, P ϭ 0.02) as independent predictors of the primary, combined endpoint. Other clinical variables, including sex, single nonresponsiveness to either ASA or clopidogrel, a history of ACS, advanced coronary (3-vessel) disease, stent type and number, total stent length Ͼ30 mm, and diabetes, were already excluded by univariate analysis (Table  3) .
Discussion
Many studies have addressed nonresponsiveness to either ASA or clopidogrel therapy (reviewed in (4, 5 ) ). So far, dual nonresponsiveness has been identified only retrospectively as a likely risk factor in patients presenting with stent thrombosis (9 ) . This single study pointed out that resistance to dual antiplatelet therapy might bear a particularly high risk of cardiac adverse events, although this conclusion was never prospectively tested. In general, only a few reports have found an association between aggregation response to ASA or clopidogrel and cardiovascular outcomes or surrogate marker concentrations after PCI (10, 11 ) . The incidence of cardiovascular events was significantly higher (P ϭ 0.03 by log-rank test) in 19 dual nonresponders (broken line) than in 163 responders (full line).
In comparison, this prospective analysis of a single-center PCI registry provided the first evidence in support of an association between dual drug resistance and cardiovascular risk. Interestingly, there were no cardiovascular events in single nonresponders to ASA. Compared to ASA, the potency of clopidogrel to inhibit platelet aggregation is greater because stable aggregation depends on ADP receptor function, whereas the inhibition of thromboxane A2 by ASA is not sufficient to prevent aggregation entirely. Therefore, it is possible that single nonresponsiveness to ASA is not associated with clinical events in the presence of a good response to clopidogrel. Consequently, it may be sufficient to test the response to clopidogrel first and then to test ASA only if nonresponsiveness to clopidogrel has been established.
Clinical baseline characteristics were not significantly associated with the response to dual antiplatelet treatment. Not unexpectedly, however, a strong trend toward dual nonresponsiveness was seen in patients with ACS or severely reduced left ventricular function. Strong platelet reactivity is frequently found in patients with acute or severe conditions and may cause dual nonresponsiveness if alternative pathways of platelet aggregation are upregulated and dominating (e.g., platelet stimulation by thrombin). In addition, previous studies found female sex, diabetes, age, smoking, and history of CAD or hypertension to be more prevalent among nonresponders to antiplatelet treatment (12 ) . These variables, however, as well as the type, number, and total length of stents, apparently did not influence the cardiovascular outcome in our study, probably because the number of patients was too small. We identified about 10% who were dual nonresponders among 182 CAD patients, and a primary endpoint occurred in 31.6% of them during follow-up. In comparison, Lev et al. (13 ) reported 6% dual nonresponders among 150 patients in whom an increase of creatine kinase-MB was monitored after elective PCI as surrogate marker for cardiovascular risk.
Aggregation responses to clopidogrel and ASA are routinely determined by whole blood aggregometry in all patients who underwent PCI in our hospital. A pharmacokinetic type of resistance is most prevalent, suggesting that individual dose adjustments may prevent cardiovascular events. For example, patients with pharmacokinetic resistance might receive another loading dose of 600 mg clopidogrel and/or 500 mg ASA (intravenous). Impedance aggregometry on the following day may then confirm improved inhibition of platelet aggregation or prompt repetition of another cycle of this treatment. The potential clinical benefits of such aggregationguided pharmacological intervention will require confirmation in controlled trials.
We conclude that dual nonresponders, identified by whole blood aggregometry after PCI, carry a high risk for subsequent cardiovascular events. Individual, intensified therapy may lower this risk but this hypothesis needs to be addressed by future trials. Whole blood impedance aggregometry is simpler than optical aggregometry because centrifugation is not required. Here, we have demonstrated its use for cardiovascular risk stratification after PCI. Notably, the purpose of this study was not a comparison of impedance aggregometry to the widely used light transmission aggregometry.
LIMITATIONS
This is the first, small pilot study addressing the association between clinical outcome and impedance aggregometry. Therefore, no data were available to use for a sample size calculation. Study subjects were consecutively recruited from an open registry. It was a heterogeneous cohort regarding the individual history of CAD and therapy. Several patients had undergone multiple interventions or had multiple episodes of acute coronary syndrome or had already been on ASA and clopidogrel therapy before enrollment. Moreover, the severity of the coronary lesions and other factors known to influence platelet function, such genetics, nutrition, or thrombin generation, were not systematically assessed. Therefore, platelet function was highly variable at the time of study inclusion. Notably, a failure of anti- platelet therapy to prevent cardiovascular events may also have been caused by mechanisms unrelated to platelet function, e.g., by noncompliance. Drug intake was not independently verified in this study.
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